Semaglutide and Addiction: What the Research Says About Cravings and Substance Use

GLP-1 medications like semaglutide have been on the market for a few years, primarily for weight loss and type 2 diabetes, and are rapidly gaining popularity.

With several success stories from a variety of users managing a healthy weight, there have been countless additional health benefits, including lower blood sugar levels and improved cardiovascular health.

Another benefit of these drugs has been coming to light with recent research — a potential treatment option for addiction. So, how does semaglutide for addiction work?

Medical Disclaimer: Semaglutide and other GLP-1 medications are not FDA-approved to treat addiction, alcohol use disorder, nicotine dependence, opioid use disorder, or other substance use disorders. This article is for educational purposes only and is not a substitute for diagnosis, treatment, or evidence-based addiction care. Anyone struggling with substance use should speak with a licensed medical provider or addiction specialist.

The Accidental Discovery: Why Weight-Loss Patients Stopped Drinking

Semaglutide has actually been around for a while now, with its use in type 2 diabetes dating back to 2017 and its role in weight management becoming established a few years later, in 2021.

The medication binds to GLP-1 receptors (proteins in the gut and brain) to mimic the effects of the GLP-1 hormone that regulates blood sugar, slows down stomach emptying, and signals fullness to the brain to reduce cravings.

Although a newer drug for weight management, another accidental discovery came about from semaglutide use in some patients, reducing addictive substance consumption.

Early studies and clinical trials have shown promising results on the ways semaglutide can reduce addiction, whether to food, alcohol, or other substances.

Some of those on the weight loss drug have also noted a general, spontaneous decrease in desire for alcohol, similar to the reduced desire for food.

This could be traced back to the different ways in which the medication works for weight and diabetes management, as the GLP-1 system in the brain also plays a role in alcohol and other substance use disorders.

How GLP-1s May Affect the Brain’s Reward System

The medication doesn’t just affect the stomach. It also targets the brain’s reward system, or more specifically, the brain chemical dopamine.

Due to the effect substances can have on dopamine, addiction creates compulsive behavior that overrides conscious choice.

Beyond the Gut: The Brain’s GLP-1 Receptors

Dopamine is referred to as the body’s “feel-good” messenger that drives motivation and reward, along with several other functions.

Rather than just producing pleasure directly, dopamine reinforces behaviors that bring about a good feeling, giving you motivation to do the thing that brings pleasure.

Essentially, dopamine works as a learning signal that strengthens the association between substances or behaviors and environmental cues.

Addictive substances — like alcohol — hijack the brain’s reward system, though, by releasing abnormally large amounts of chemicals like dopamine.

This trains the brain to repeat the action that brought on good feelings, and in this case, consume more addictive substances, creating a cycle.

You can think of the brain on addiction as a broken thermostat, where the heater (dopamine) is stuck on high.

Semaglutide doesn’t cut the power to the thermostat; it repairs it to return the brain’s dopamine levels to a comfortable temperature.

Dampening the Dopamine Spike

This is where semaglutide’s mechanisms on dopamine and the brain’s GLP-1 receptors come into play.

Dopamine can be released through any number of actions that bring about pleasure, especially through addictive substances, whether it’s food or alcohol.

Semaglutide decreases the craving for an addictive substance by changing the mesolimbic dopamine system, or the brain’s reward pathway, by activating GLP-1 receptors in the ventral tegmental area (VTA) and nucleus accumbens (NAc).

In other words, semaglutide dampens or suppresses dopamine signals from addictive substances in two key areas of the brain’s reward system.

Alcohol Use Disorder (AUD): Where the Research Is Strongest

Alcohol use disorder (AUD) can have very serious health and social consequences and should be treated by a well-trained health care provider. A person suffering with AUD should not forego treatment in the hopes of self-treating with tools such as GLP-1.

---

---

Early trials and studies have shown promising results in low-dose, weekly injections of semaglutide reducing cravings and consumption in those with alcohol use disorder.

One study in JAMA Psychiatry found that once-weekly low-dose semaglutide reduced not only the amount of alcohol consumed overall but also cravings to drink and heavy drinking days.

While the initial study was small and only conducted on fewer than 50 participants, the findings opened up discussion of GLP-1 for alcohol use disorder (AUD).

One study showed up to a 56 percent lower risk of alcohol use disorder incidence and recurrence in those treated with semaglutide.

Another study of more than 220,000 individuals found that semaglutide was associated with the lowest risk of hospitalization from AUD.

But semaglutide may not just reduce addiction to alcohol.

The weight loss medication has also been connected with reduced nicotine cravings and overall lower tobacco use, as well as a lower risk of needing medications that curb smoking in those with type 2 diabetes.

A study of more than 33,000 patients showed that semaglutide use had significantly lowered the risk of opioid overdose in people with type 2 diabetes and opioid use disorder

Results from the 2026 STAR Clinical Trials

Other clinical trials have shown the impact of semaglutide on alcohol use disorder, resulting in a significant reduction in heavy drinking days and substance-related hospitalizations over the course of 12 weeks.

Notably, a study of over 600,000 U.S. veterans published in The BMJ found that GLP-1 drugs like semaglutide reduced the risk of new substance use disorders by 14 percent across all substance use conditions.

Specifically, the study showed an 18 percent lower risk for alcohol use, 20 percent for nicotine and cocaine, and a 25 percent lower risk for opioid addiction.

From Food Cravings to Substance Cravings: What GLP-1 Research Suggests

If you’re using semaglutide or have read up on the drug, you may have heard the term “food noise”, a phrase that describes obsessive or intrusive thoughts around food and eating.

How semaglutide works to reduce “food noise” and cravings is through dopamine and the brain’s reward system.

This mechanism extends to “drug noise”, or constant cravings for substances that bring on a dopamine spike.

Semaglutide directly influences VTA dopamine neurons that project to the nucleus accumbens (NAc), regulating hedonic food motivation and craving.

But it’s not just intrusive thoughts around food that semaglutide affects. The medication acts on any substance that spikes dopamine by silencing the constant mental background chatter of addiction.

Just as semaglutide reduces cravings for food, it’s also been shown to reduce any type of craving by lessening the effects of dopamine.

Why Addiction Treatment Goes Beyond Willpower

These findings are promising for several reasons, one of which is that current treatments for addiction often only manage symptoms rather than the underlying cause of cravings.

Older medications, like Disulfiram for alcohol use disorder, work to reduce consumption by making the user have a severe, unpleasant reaction, resulting in flushing, nausea, vomiting, and palpitations.

Semaglutide, on the other hand, simply creates indifference to substances, almost as if making the user “forget” they want the substance by turning the volume down on dopamine.

Beyond typical pharmaceutical options for substance use disorders, willpower alone is rarely a successful treatment strategy for addiction, which is a biological, brain-based disease.

Research Limits and Safety Considerations

While off-label use (using a drug for a different condition than the one it was approved for) of semaglutide for substance use is rising, the weight loss medication has yet to be FDA-approved for addiction treatment.

Semaglutide is not without its own limitations, though. The gastrointestinal side effects, such as nausea, vomiting, constipation, diarrhea, and stomach pain, can be difficult for some patients to manage.

And while initial studies are promising, more large-scale clinical trials are needed to determine this treatment's long-term efficacy and safety.

Semgalutide could be promising as an addiction treatment, not on its own, but as part of a toolkit that includes standardized treatments like behavioral therapy.